Audited Financial Results as on March 31, 2026
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts more than Nifty Microcap 250 and 7.7 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Camlin Fine Sciences reported mixed results for FY2026. On a standalone basis, revenue declined to Rs 83,792 lakh from Rs 88,649 lakh in the prior year. The company posted a standalone loss of Rs 1,664 lakh, slightly better than the Rs 1,727 lakh loss in FY2025. On a consolidated basis (including the newly acquired Vinpai subsidiary from November 2025), revenue grew to Rs 172,331 lakh from Rs 162,869 lakh. However, consolidated profit turned into a loss of Rs 665 lakh versus a profit of Rs 6,413 lakh in FY2025, impacted by exceptional items including fire loss (Rs 763 lakh), acquisition costs (Rs 406 lakh), and doubtful loan provisions. Key discontinued operations include CFS Europe SpA (liquidated in March 2026) and CFS Wanglong, China. The statutory auditor issued an unmodified (clean) opinion. The company also appointed a new CFO and completed the Vinpai acquisition for Rs 10,171 lakh.
The company continues to burn cash on a standalone basis with revenue declining, though losses have narrowed. The consolidated results show the Vinpai acquisition is adding scale but near-term profitability is impacted by exceptional items and integration costs. Shareholders should monitor if the company can achieve sustainable profitability next fiscal.